Angle Share News (AGL)

Angle wins cancer monitoring contract for Parasortix system

(Alliance News) - Angle PLC on Wednesday said it has secured further business with its "first large scale pharma services" customer.

TRADING UPDATES: Valereum opens NFT market; Conygar considers raising

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

IN BRIEF: Angle's Parsortix performs well on prostate cancer patients

Angle PLC - Surrey, England-based medical diagnostics company - Notes researchers at King's College London published data investigating the role of invasive cellular protrusion, known as invadopodia, activity in prostate cancer, and a potential role in the formation of circulating tumour cells. Researchers used Angle's Parsortix system's ability to isolate CTCs from the blood of prostate cancer patients. Parsortix system isolates CTCs in 94% of prostate cancer patients, showing some association with matrix degradation and invasive cellular protrusion formation. This may allow novel therapeutic development targeting the mechanisms of invadopodia and reducing metastatic spread of the cancer, it says.

IN BRIEF: Angle partners with US urology group for Parasortix study

Angle PLC - Surrey, England-based medical diagnostics company - Establishes partnership with MidLantic Urology to evaluate the use of its Parasortix system in prostate cancer clinical studies. MidLantic is as an affiliate of special urology services provider Solaris, which has over 500 clinical urology providers across 179 locations in the US, with over 729,000 annual patients. Angle hopes the collaboration will "enable potential sales" to Solaris' patient base. The first study is expected to start in the third quarter of 2022, with results to be available in 2023.

TRADING UPDATES: Savannah Energy to develop new projects in Chad

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

IN BRIEF: Angle shares rocket as Parasortix receives US FDA approval

Angle PLC - Surrey, England-based medical diagnostics company - Receives approval from the US Food & Drug Administration for the use of its Parasortix system for use in metastatic breast cancer patients. Parasortix isolates circulating tumour cells from the blood which can aid in the diagnosis, characterisation and monitoring of cancer, and do so in a much less invasive fashion than traditional tissue biospy.

LONDON MARKET CLOSE: Stocks rise ahead of US Fed meeting minutes

(Alliance News) - Stocks in London ended mostly higher on Wednesday as market participants look ahead to the latest minutes from the US Federal Reserve at 1900 BST.

Angle's Parsortix to be used in 'significant' prostate cancer study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that Prostate Cancer UK has approved funding for a "significant" clinical study at the Barts Cancer Institute of the Queen Mary University of London.

IN BRIEF: Cancer study using Angle's Parasortix secures funding

Angle PLC - Surrey, England-based medical diagnostics company - Says Prostate Cancer UK has given a GBP750,000 grant for a clinical study at Barts Cancer Institute, Queen Mary University of London. The trial will follow 200 men with localised prostate cancer over five years, assessed using Angle's Parsortix system, in bid to see whether the cancer will eventually spread.

EARNINGS UPDATES: Brave Bison notes first profit; Angle widens loss

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

UK earnings, trading statements calendar - next 7 days

TRADING UPDATES: Yooma, Love Hemp in UK boost; Peel Hunt tops forecast

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

IN BRIEF: Angle's Parsortix can help with cancer treatment options

Angle PLC - Surrey, England-based medical diagnostics company - Notes University of Maryland Marlene and Stewart Greenebaum NCI Comprehensive Cancer Institute has published results of work undertaken in preclinical models of triple-negative breast cancer. Findings show isolation of live circulating tumour cells from a simple blood draw, using Angle's Parsortix system, can provide rapid information on patient response to existing chemotherapy treatments that can target metastasis more effectively than tumour growth.

TRADING UPDATES: Europa eyes fundraise; Eastinco extends long stop

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

TRADING UPDATES: Angle US lab boost; Corcel to capitalise on nickel

(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News: